Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
New York, USA, April 16, 2026 (GLOBE NEWSWIRE) -- Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight The...
-
This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn. Boehringer Ingelheim today announced that The New England Journal of Medicine (NEJM) published results...
-
Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential Statistical assessments point to high...
-
Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfolios, welches Immunmodulatoren,...
-
Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates,...
-
Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer...
-
This press release is not intended for UK media HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1...
-
Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis FDA Fast Track designation offers clear pathway for ateganosine...
-
~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in...
-
NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...